Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4199-4207

  Roth, Thomas ^a,c   Morningstar, Marshall L ^a   Boyer, Paul L ^a   Hughes, Stephen H ^a   Buckheit Jr , Robert W ^b   Michejda, Christopher J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,6 DIFLUOROBENZYL) 2 (2,6 DIFLUOROPHENYL) 4 METHYLBENZIMIDAZOLE; 1 (2,6 DIFLUOROPHENYL) 1H,3H THIAZO[3,4A]BENZIMIDAZOLE; 8 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYLIMIDAZO[4,5,1 JK][1,4]BENZODIAZEPIN 2(1H)ONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; BENZIMIDAZOLES; CELL LINE; CYTOPROTECTION; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0031463691     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970096g     Document Type: Article

References (25)

1. Katz, R. A.; Skalka, A. M. The retroviral enzymes. Annu. Rev. Biochem. 1994, 63, 133-73.
2. Vaishnav, Y. N.; Wong-Stall, F. The biochemistry of AIDS. Annu. Rev. Biochem. 1991, 60, 577-630.
3. De Clercq, E. HIV-1 specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 1993, 13, 229-258.
4. De Clereq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
5. Schinazi, R. F. Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspect. Drug Discov. Des. 1993, 1, 151-180.
6. Young, S. D. Nonnucleoside inhibitors of HIV-1 reverse transcriptase. Perspect. Drug Discov. Des. 1993, 1, 181-192.
7. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Aries, K.; Janssen, P. A. J.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
8. Smith, M. B. K; Rouzer, C. A.; Taneyhill, L. A.; Smith, N. A.; Hughes, S. H.; Boyer, P. L.; Janssen, P. A. J.; Moereels, H.; Koymans, L.; Arnold, E.; Ding, J.; Das, K.; Zhang, W.; Michejda, C. J.; Smith, R. H. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: Total energy of complexation as a predictor of drug placement and activity. Protein Sci. 1995, 4, 2203-2222.
9. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R86183 complex reveals remarkable similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol. 1995, 2, 407-415.
10. Nanni, R. G.; Ding, J.; Jacobo-Molina, A.; Hughes, S. H.; Arnold, E. Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect. Drug Discovery Des. 1993, 1, 129-150.
11. Chimirri, A.; Grasso, S.; Monforte, A.-M.; Monforte, P.; Zappala, M. Anti-HIV agents. I. Synthesis and in vitro anti-HIV evaluation of novel lH,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 1991, 46, 817-823.
12. Chimirri, A.; Grasso, S.; Monforte, A.-M.; Monforte, P.; Zappala, M. Anti-HIV agents. II. Synthesis and in vitro anti-HIV evaluation of novel 1H, 3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 1991, 46, 925-933.
13. Buckheit, R. W.; Hollingshead, M. G.; Germany-Decker, J.; White, E. L.; McMahon, J. B.; Allen, L. B.; ROSS, L. J.; Decker, W. D.; Westbrook, L.; Shannon, W. M.; Weislow, O.; Bader, J. P.; Boyd, M. R. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 1993, 21, 247-265
14. El Dareer, S. M.; Tillery, K. F.; Rose, L. M.; Posey, C. F.; Struck, R. F.; Stiller, S. W.; Hill, D. L. Metabolism and Disposition of a thiazolobenzimidazole active against Human Immunodeficiency Virus-1. Drug Metab. Dispos. 1993, 21, 231-235.
15. Boyer, P. L.; Currens, M. J.; McMahon, J. B.; Boyd, M. R.; Hughes, S. H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 1993, 67, 2412-2420.
16. Buckheit, R. W.; Fliakas-Boltz, V.; Decker, W. D.; Roberson, J. L.; Stup, T. L.; Pyle, C, A.; White, E. L.; McMahon, J. B.; Currens, M. J.; Boyd, M. R.; Bader, J. P. Comparative anti-HIV evaluation of diverse HIV-1 specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. 1995, 26, 117-132.
17. De Clercq, E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharm. 1994, 47, 155-169
18. Hizi, A.; McGill, C.; Hughes, S. H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc. Natl Acad. Sci. U.S.A. 1988, 85, 1218-1222.
19. Chimirri, A.; Grasso, S.; Monforte, A. M.; Monforte, P.; Zappala, M. Thiazolobenzimidazoles as non-nucleoside HIV-1 RT inhibitors. Abstracts of the II Congresso Congiunto Italiano-Spagnolo di Chimica farmaceutica, Ferrara, Italy, August 30-September 3, 1995; ML20.
20. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 557-586.
21. McMahon, J. B.; Gulakowski, R. J.; Weislow, O. S.; Schultz, R. J.; Narayanan, V. L.; Clanton, D. J.; Pedemonte, R.; Wassmundt, F. W.; Buckheit, R. W.; Decker, W. D.; White, E. L.; Bader, J. P.; Boyd, M. R. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 754-760.
22. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Rooney, C. S.; Balani, S. K.; Condra, J. H.; Emini, E. A.; Goldman, M. E.; Greenlee, W. J.; O'Brien, J. A,; Sardana, V. V.; Schleif, W. A.; Theoharides, A. D.; Anderson, P. S. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: A Novel, Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. J. Med. Chem. 1993, 36, 1291-1294.
23. Fischer, A; King, M. J.; Robinson, F. P. Inductive substituent constants from dissociation of methyl-substituted 3-picolinium ions. Can. J. Chem. 1978, 56, 3068-71.
24. Pauwels, R.; Andries, K.; Debyser, Z.; Van Daele, P.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Hekants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of a-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
25. Yang, S.; Fliakas-Boltz, V.; Bader, J. P.; Buckheit, R. W. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Leukemia 1995, Suppl. 1, S75-S85.